Law Offices of Thomas J. Lamb

  • About Firm
  • Practice Areas
  • Free Case Evaluation
  • Quick Contact Form
  • Frequently Asked Questions
  • Attorney Tom Lamb

Prolia & Xgeva: QT Interval Prolongation Associated With Hypocalcemia

August 19, 2016 By Law Offices of Thomas J. Lamb, P.A.

Denosumab is the active ingredient for Prolia as well as Xgeva, with Prolia being a treatment for osteoporosis and osteopenia, and Xgeva being a drug used for the prevention of skeletal-related events in adults with bone metastases from solid tumors. Both Prolia and Xgeva come from biotech pharmaceutical company Amgen Inc.

An emerging drug safety issue was recently addressed by Australia’s Therapeutic Goods Administration (TGA), and was initially identified by that drug regulator during an assessment of adverse event reports relating to denosumab (Prolia and Xgeva).

Specifically, there are some new apparent side effects of Prolia as well as Xgeva, QT interval prolongation and severe symptomatic hypocalcemia.

From this August 12, 2016 article, “Australia’s TGA issues warning on denosumab and QT prolongation”, published on the ThePharmaLetter(subscription required) website, we get this detailed information:

Product information update

Hypocalcemia is a known effect of denosumab and was already captured in the Product Information (PI). However, there was previously no reference to QT prolongation, which is a potentially life-threatening disorder, or to severe symptomatic hypocalcemia.

The following sections of the PI have been updated: [Precautions and Adverse Effects]….

This updated information has harmonized the Australian PIs with the European Union Summary of Product Characteristics for these products.

We will continue to monitor this emerging drug safety issue for Prolia and Xgeva, including to watch for any similar regulatory action by the FDA here in the US.

[Read this article in full at original source]

Filed Under: Unsafe Drugs Tagged With: Hypocalcemia, Prolia, QT Interval Prolongation, Xgeva

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.